Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

MiniMax Group Inc. shares surged in Hong Kong, buoyed by growing investor confidence in the technology offered by China’s generative AI startups. The stock gained as much as 30%, before closing up 25% ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) came under pressure after regulatory ...

The MiniMax M2.5 is an advanced AI model designed to balance high performance with cost efficiency, as explained by Caleb Writes Code. Building on its predecessor, the M2.1, this model incorporates a ...

Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) stock tumbled 12% Wednesday morning after regulatory filings revealed that NVIDIA (NASDAQ:NVDA) had completely divested its stake in the ...

The Minimax M2.5 is a compact yet capable AI model that combines affordability with competitive performance, as detailed by Sam Witteveen. With a processing cost of just $1 per hour for 100 tokens per ...

MiniMax shares surged after revenue beat expectations in its first set of results following its listing. Shares of the Chinese artificial-intelligence company rose 18% to 884.00 Hong Kong dollars, or ...

Anthropic dropped a bombshell on the artificial intelligence industry Monday, publicly accusing three prominent Chinese AI laboratories — DeepSeek, Moonshot AI, and MiniMax — of orchestrating ...